Active
    Mainboard

    Corona Remedies Ltd

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    Corona Remedies Ltd IPO opened on 08 Dec 2025 and closed on 10 Dec 2025, with a price band of ₹1008–₹1,062 per share. The IPO had a lot size of 14 shares, requiring a minimum investment of ₹14,868 per lot at the upper price band. The issue size was ₹655.37 crore, and the shares get listed on 15 Dec 2025.

    Corona Remedies Ltd IPO Details

    Listing Date

    15 Dec 2025

    Bid Price

    ₹1008 - ₹1,062

    Lot Size

    14 Shares

    Minimum Investment

    ₹14,868 / Lot

    Issue Size

    ₹655.37 Cr

    Employee Discount

    ₹54 per share

    Key Dates to Track

        Here are the important dates you need to know in order to participate in this IPO

    tick

    Offer Start Date

    8th Dec

    tick

    Offer End Date

    10th Dec

    tick

    Allotment Date

    11th Dec

    tick

    Refund Initiation

    12th Dec

    tick

    Demat Transfer

    12th Dec

    tick

    Listing Date

    15th Dec

    About Corona Remedies Ltd IPO

    Incorporated in August 2004, Corona Remedies Limited operates as a pharmaceutical company with activities in the development, manufacturing, and marketing of branded formulations. The company’s product portfolio covers multiple therapeutic segments, including women’s healthcare, cardio-diabeto, pain management, urology, and other multispecialty areas. As of June 30, 2025, the portfolio consisted of 71 brands across these categories, including products in vitamins and minerals, nutrition, gastrointestinal, and respiratory segments. The company engages with healthcare professionals through a marketing and distribution network present across 22 states, supported by 2,671 medical representatives. This network is positioned to facilitate product availability in different regions of the Indian pharmaceutical market.
     

    Corona Remedies Limited operates two manufacturing facilities located in Gujarat, with a reported aggregate installed formulation capacity of 1,285.44 million units per annum. Based on available domestic sales data for MAT June 2025, the women’s healthcare segment accounted for 28.56% of sales at ₹4,080.26 million, cardio-diabeto products accounted for 23.38% at ₹3,339.96 million, pain management contributed 11.79% at ₹1,684.38 million, and the urology segment accounted for 4.53% at ₹646.65 million. These figures reflect the contribution of individual therapeutic segments within the company’s product basket. The information provided reflects publicly available disclosures and can be cross-checked with official filings for accuracy.

    Corona Remedies Ltd Shareholding Pattern

      Pre-Issue Post-Issue
    Promoter Group 72.5% 69%
    Public Group 27.5% 31%

    Corona Remedies Ltd IPO Reservation

    QIB Shares Offered 12,23,203 (19.82%)
    NII (HNI) Shares Offered 9,17,403 (14.87%)
    Retail Shares Offered 21,40,606 (34.69%)
    Anchor Investor Shares Offered 18,34,805 (29.73%)
    Total Shares Offered 61,71,102
    Total Shares With Anchor Investor 61,71,102

    Corona Remedies Ltd IPO Lot Size

    Application Lots Shares Amount
    Retail (Min) 1 14 ₹14,868
    Retail (Max) 13 182 ₹1,93,284
    S HNI (Min) 14 196 ₹2,08,152
    S HNI (Max) 67 938 ₹9,96,156
    B HNI (MIN) 68 952 ₹10,11,024

    Corona Remedies Ltd IPO registrar

    Bigshare Services Pvt Ltd
    Phone Number +91 22626 38200
    Email Id investor@bigshareonline.com
    Website www.bigshareonline.com

    Corona Remedies Ltd IPO Lead Manager

    1. JM Financial Ltd

    2. IIFL Capital Services Ltd

    3. Kotak Mahindra Capital Co. Ltd

    Corona Remedies Ltd Financial Information

    March 31, 2026 March 31, 2025 March 31, 2024
    Net Worth ₹746.86 Cr ₹606.34 Cr ₹480.41 Cr
    Reserves and Surplus ₹685.7 Cr ₹545.18 Cr ₹419.25 Cr
    Total Borrowing ₹142.86 Cr ₹62.7 Cr ₹134.14 Cr

    Strength of Corona Remedies Ltd

    • Second fastest growing company within the top 30 pharmaceutical companies in the Indian pharmaceutical market by domestic sales between MAT June 2022 and MAT June 2025.
    • Demonstrated capabilities of building a diversified portfolio, including "engine" brands, in our targeted therapy areas.
    • Pan-India sales network and marketing strategy focused on the "middle of the pyramid" target market.
    • Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.
    • Qualified, experienced and entrepreneurial management team supported by marquee investors.

    Risks Involved

    • The therapeutic areas of women's healthcare, cardio-diabeto and pain management contributed to an aggregate of Rs.2,257.26 million (or 65.14%) and Rs.7,465.54 million (or 62.40%) of our revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025, respectively. If our products in these or other therapeutic areas which contribute significantly to our revenue from operations do not perform as expected or if competing products become available and gain wider market acceptance, our business, results of operations, financial condition and cash flows may be adversely affected.
    • Our 27 "engine" brands (and in particular, our B-29 and Myoril brands) accounted for 72.34% of our domestic sales during the MAT June 2025 period, and any adverse developments affecting the sales of our "engine" brands could have an adverse effect on our business, results of operations, financial condition and cash flows.
    • The company derive a significant majority of its revenue from the company operations within India (constituting 96.34% and 96.33% of the company revenue from operations during the three months ended June 30, 2025 and the Financial Year 2025, respectively). In the event of a fall in demand for the company products in India, or if its fail to successfully expand into international markets, the company business, results of operations, financial conditions and cash flows may be adversely affected.
    • A significant portion of the company domestic sales are concentrated in the states of Gujarat, Maharashtra, Chhattisgarh, Goa and Madhya Pradesh (accounting for 47.30% of the company domestic sales for MAT June 2025). Any adverse developments affecting its sales in these regions could has an adverse effect on the company business, results of operations, financial condition and cash flows.
    • 70.10% of Its domestic sales for MAT June 2025 were derived from chronic and sub-chronic therapeutic segments, which are subject to risks and uncertainties that could adversely affect the company business, results of operations, financial condition and cash flows.
    • Its depend on third-party suppliers to procure the company raw materials and finished goods, with whom the company does not has long term contracts, with the company total purchases aggregating to 19.87% and 27.96% of its total expenses for the three months ended June 30, 2025 and the Financial Year 2025, respectively. Further, the company relies on La Chandra Pharmalab Private Limited, its Associate and Group Company, for the supply of certain active pharmaceutical ingredients in the comapny women's healthcare therapeutic area. its cannot assure you that the company will be in a position to fully control or direct the operations of such suppliers to ensure an uninterrupted supply of raw materials and APIs.
    • As of June 30, 2025, with a portfolio of 71 brands, its held 194 registered trademarks, with 29 pending trademark applications and 67 opposed/ objected/ refused / abandoned trademarks under certain classes of trademarks. If its unable to obtain trademarks for the company products and brands or protect other proprietary information, the company business, results of operations, financial condition and cash flows may be adversely affected.
    • The company required to obtain, maintain or renew its statutory and regulatory licenses, permits and approvals required to operate the company operations. If its fail to obtain, maintain or renew the required licenses, permits and approvals, it may adversely affect the company business, results of operations, financial condition and cash flows.
    • Proceeds from the Offer will not be available to it.
    • As of June 30, 2025, its engaged 22 carrying and forwarding agents for the sale of the company products across the regions in which the company market its products, with the company five largest C&F agents contributing to 43.30% and 44.35% of Its revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025. The loss of the company C&F agents, the deterioration of their financial condition or prospects, a reduction in their demand for the company products or its inability to maintain and increase the number of the company arrangements for the distribution of its products could adversely affect the company business, results of operations, financial conditions and cash flows.

    Invest in IPOs with ease

    Sign-in to invest with your demat account, or set up a new demat account for free

    Industry Outlook of Corona Remedies IPO

    • The Indian domestic formulation segment in Financial Year 2025 reported an estimated market value of around ₹2.3 trillion, representing close to 2% of the global pharmaceutical market size.

    • The sector operates within a manufacturing ecosystem that includes production facilities with advanced technology and a specialised workforce engaged in pharmaceutical development.

    • Consumption within the domestic formulation market recorded a compound annual growth rate (CAGR) of about 9% during Financial Years 2020 to 2025, based on available sector data.

    • Market projections sourced from industry estimates indicate a possible CAGR range of 8–9% for the period leading to Financial Year 2030.

    • The estimated value range for the market by Financial Year 2030 has been placed between ₹3.3 trillion and ₹3.5 trillion in published assessments.

    • These projections reflect demand factors that include higher reported cases of long-duration health conditions, rising awareness levels, and wider access to healthcare services in India.


    Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Corona Remedies IPO.    

    Explore Other IPOs

    • Current IPOs
    • Upcoming IPOs
    • Closed IPOs
    • IPO Performance
    • All
    • MainBoard
    • SME
    CORE4 ENGINEERS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    23rd Oct 2026 - 10th Oct 2026
    Price Range
    ₹88.0 - 93.0
    IPO Size
    ₹54,82,00,000
    • All
    • MainBoard
    • SME
    Bidding Period
    26th Oct 2026 - 10th Oct 2026
    Price Range
    ₹1585.0 - 1665.0
    IPO Size
    ₹12,00,00,00,000
    BLS Polymers Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    27th Oct 2026 - 10th Oct 2026
    Price Range
    ₹142.0 - 150.0
    IPO Size
    ₹2,55,00,00,128
    Bidding Period
    27th Oct 2026 - 10th Oct 2026
    Price Range
    ₹313.0 - 330.0
    IPO Size
    ₹6,67,53,00,352
    Wiscon Industries Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    27th Oct 2026 - 10th Oct 2026
    Price Range
    ₹194.0 - 204.0
    IPO Size
    ₹1,10,00,00,000
    Carver Roboweld Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    28th Oct 2026 - 10th Oct 2026
    Price Range
    ₹76.0 - 80.0
    IPO Size
    ₹28,29,00,000
    M K Sons Fine Jewels Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹153.0 - 162.0
    IPO Size
    ₹2,75,39,99,872
    Bidding Period
    29th Oct 2026 - 11th Nov 2026
    Price Range
    ₹78.0 - 82.0
    IPO Size
    ₹1,83,05,99,936
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Advanced SysTek Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Advanta Enterprises Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Agilus Diagnostics Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    AGS Health Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Airox Technologies Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    AITMC Ventures Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Ajay Poly Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Allchem Lifescience Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    NO ACTIVE IPO HERE
    • All
    • MainBoard
    • SME
    JIO PLATFORMS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    21st Oct 2026 - 10th Oct 2026
    Price Range
    ₹1065.0 - 1119.0
    IPO Size
    ₹3,02,13,00,03,968
    PARAS HEALTHCARE LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    21st Oct 2026 - 10th Oct 2026
    Price Range
    ₹660.0 - 693.0
    IPO Size
    ₹14,49,99,99,744
    Bidding Period
    15th Oct 2026 - 10th Oct 2026
    Price Range
    ₹327.0 - 344.0
    IPO Size
    ₹4,75,48,00,128
    Bidding Period
    15th Oct 2026 - 10th Oct 2026
    Price Range
    ₹558.0 - 586.0
    IPO Size
    ₹25,33,80,99,712
    SHELLZ INDIA LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    15th Oct 2026 - 10th Oct 2026
    Price Range
    ₹170.0 - 179.0
    IPO Size
    ₹59,97,00,032
    TONBO IMAGING INDIA LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    15th Oct 2026 - 10th Oct 2026
    Price Range
    ₹665.0 - 700.0
    IPO Size
    ₹8,52,17,99,680
    Bidding Period
    15th Oct 2026 - 10th Oct 2026
    Price Range
    ₹143.0 - 151.0
    IPO Size
    ₹50,12,33,00,864
    FUSION CX LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    14th Oct 2026 - 10th Oct 2026
    Price Range
    ₹275.0 - 289.0
    IPO Size
    ₹7,02,00,00,256
    Bidding Period
    14th Oct 2026 - 10th Oct 2026
    Price Range
    ₹105.0 - 112.0
    IPO Size
    ₹1,16,04,99,968
    HD FIRE PROTECT LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    13th Oct 2026 - 10th Oct 2026
    Price Range
    ₹258.0 - 271.0
    IPO Size
    ₹7,12,12,99,968
    VAIBHAV VYAPAAR LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    13th Oct 2026 - 10th Oct 2026
    Price Range
    ₹51.0 - 54.0
    IPO Size
    ₹42,10,00,000
    Bidding Period
    5th Oct 2026 - 10th Oct 2026
    Price Range
    ₹77.0 - 82.0
    IPO Size
    ₹34,99,00,032
    PARAMOUNT SYNTEX LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    30th Sep 2026 - 10th Oct 2026
    Price Range
    ₹119.0 - 127.0
    IPO Size
    ₹81,79,00,032
    Bidding Period
    30th Sep 2026 - 10th Oct 2026
    Price Range
    ₹186.0 - 196.0
    IPO Size
    ₹1,21,68,99,968
    TNA SOLUTIONS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    30th Sep 2026 - 10th Oct 2026
    Price Range
    ₹66.0 - 70.0
    IPO Size
    ₹37,86,00,000
    SHREE TNB POLYMERS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    28th Sep 2026 - 10th Oct 2026
    Price Range
    ₹50.0 - 53.0
    IPO Size
    ₹31,80,00,000
    SJP ULTRASONICS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    30th Sep 2026 - 10th Oct 2026
    Price Range
    ₹67.0 - 67.0
    IPO Size
    ₹23,45,00,000
    Bidding Period
    30th Sep 2026 - 10th Oct 2026
    Price Range
    ₹55.0 - 55.0
    IPO Size
    ₹21,78,00,000
    VISHAL NIRMITI LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    30th Sep 2026 - 10th Oct 2026
    Price Range
    ₹208.0 - 220.0
    IPO Size
    ₹1,78,00,00,000
    EVENTIONS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    30th Sep 2026 - 10th Oct 2026
    Price Range
    ₹112.0 - 118.0
    IPO Size
    ₹38,12,00,000
    • All
    • MainBoard
    • SME
    Issue Prize
    1785.00
    Listing Day Close
    1818.00(1.85%)
    LAPL AUTOMOTIVE LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    94.00
    Listing Day Close
    128.29(36.17%)
    Issue Prize
    344.00
    Listing Day Close
    378.20(9.88%)
    Issue Prize
    586.00
    Listing Day Close
    576.35(-1.71%)
    SHELLZ INDIA LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    179.00
    Listing Day Close
    170.05(-5.03%)
    TONBO IMAGING INDIA LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    700.00
    Listing Day Close
    1133.65(62.00%)
    Issue Prize
    151.00
    Listing Day Close
    138.30(-8.61%)
    FUSION CX LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    289.00
    Listing Day Close
    289.75(0.35%)
    HD FIRE PROTECT LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    271.00
    Listing Day Close
    307.20(13.28%)
    Issue Prize
    112.00
    Listing Day Close
    113.70(1.79%)
    VAIBHAV VYAPAAR LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    54.00
    Listing Day Close
    53.05(-1.85%)
    Issue Prize
    82.00
    Listing Day Close
    76.00(-7.32%)
    PARAMOUNT SYNTEX LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    127.00
    Listing Day Close
    109.25(-14.17%)
    Issue Prize
    196.00
    Listing Day Close
    232.05(18.37%)
    TNA SOLUTIONS LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    70.00
    Listing Day Close
    58.80(-15.71%)
    SHREE TNB POLYMERS LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    53.00
    Listing Day Close
    57.00(7.55%)
    SJP ULTRASONICS LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    67.00
    Listing Day Close
    73.01(8.96%)
    Issue Prize
    55.00
    Listing Day Close
    99.18(80.00%)
    VISHAL NIRMITI LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    220.00
    Listing Day Close
    204.25(-7.27%)
    EVENTIONS LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    118.00
    Listing Day Close
    105.45(-11.02%)

    Frequently Asked Questions

    What is Corona Remedies Ltd IPO?

    Corona Remedies Ltd IPO is a Mainboard IPO of 61,71,102 equity shares of a face value of ₹10 aggregating up to ₹655.37 Crores. The issue is priced at ₹1008 to ₹1062 per share. The minimum order quantity is 14 Shares. The IPO opens on December 08, 2025, and closes on December 10, 2025. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

    When Corona Remedies Ltd IPO will open?

    The Corona Remedies Ltd IPO opens on December 08, 2025 and closes on December 10, 2025.

    What is the lot size of Corona Remedies Ltd?

    Corona Remedies Ltd lot size is 14 shares, and the minimum amount required is ₹14,868.

    How to apply for Corona Remedies Ltd IPO?

    You can apply in Corona Remedies Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

    • Login to Bajaj Broking account App/Website & click on IPO
    • Enter the number of lots and price at which you wish to apply.
    • Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
    • You will receive a mandate notification to block funds in your UPI app.
    • Approve the mandate request on your UPI and funds will be blocked.

    When is Corona Remedies Ltd IPO allotment?

    The finalization of Basis of Allotment for Corona Remedies Ltd IPO will be done on December 11, 2025, and the allotted shares will be credited to your demat account by December 12, 2025.

    When is Corona Remedies Ltd IPO listing date?

    The Corona Remedies Ltd listing date is December 15, 2025.

    Who is the registrar of Corona Remedies Ltd IPO?

    The registrar of Corona Remedies Ltd IPO is Bigshare Services Pvt Ltd

    Which company is the book-running lead manager of the IPO?

    JM Financial Ltd,IIFL Capital Services Ltd,Kotak Mahindra Capital Co. Ltd will be the book-running lead manager of this IPO.

    What is the fresh issue of Corona Remedies Ltd IPO?

    The fresh issue size is ₹[-] Crores equity shares.

    What minimum lot size can retail subscribers subscribe to Corona Remedies Ltd?

    Retail investors can subscribe to a minimum of one lot, 14 shares and ₹14,868 amount.

    How can I approve the UPI mandate request for Corona Remedies Ltd IPO?

    To apply for Corona Remedies Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

    What is the price range of Corona Remedies Ltd?

    The price of each Corona Remedies Ltd share will be ranging in between ₹1008 to ₹1062 per share.

    What is the cut-off time for the UPI mandate for Corona Remedies Ltd IPO?

    The cut-off time for the UPI mandate confirmation is 5:00 PM, December 10, 2025.

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Access Research Backed Stock Recommendations

    +91

    |

    Open Your Free Demat Account

    Access Research Backed Stock Recommendations

    +91

    |